ImmunityBio (IBRX) Receivables (2014 - 2026)

ImmunityBio (IBRX) has 8 years of Receivables data on file, last reported at $43.3 million in Q1 2026.

• Receivables for Q1 2026 came in at $43.3 million, up 147.95% year-over-year; the trailing twelve-month figure through Mar 2026 was $43.3 million (up 147.95% YoY), and the FY2025 annual result was $42.6 million, up 1564.73% from the prior year.
• Receivables grew to $43.3 million in Q1 2026 per IBRX's latest filing, from $42.6 million in the prior quarter.
• Over five years, Receivables peaked at $43.3 million in Q1 2026 and troughed at $2.0 million in Q4 2023.
• A 5-year average of $14.1 million and a median of $3.2 million in 2023 frame the typical range for Receivables.
• The sharpest annual moves came in 2023 and 2025: Receivables slumped 36.71% in 2023, then jumped 1564.73% in 2025.
• A 5-year view of Receivables shows it stood at $3.2 million in 2022, then tumbled by 36.71% to $2.0 million in 2023, then rose by 26.8% to $2.6 million in 2024, then jumped by 1564.73% to $42.6 million in 2025, then advanced by 1.54% to $43.3 million in 2026.
• Business Quant data shows IBRX's Receivables at $43.3 million in Q1 2026, $42.6 million in Q4 2025, and $33.7 million in Q3 2025.